secwatch.observer — SEC 8-K summary
======================================

Issuer:     PFIZER INC (PFE)
CIK:        0000078003
Form:       8-K
Filed at:   2023-10-13T23:59:59+00:00
Accession:  0000078003-23-000099
Event type: earnings
Sentiment:  negative
Materiality: 1.00
Item codes: 2.02, 2.05, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pfizer cuts FY2023 revenue guide by $9B, records $5.5B COVID write-off, amends Paxlovid deal
--------------------------------------------------------------------------------

- Revises 2023 revenue to $58-61B (from $67-70B); Paxlovid revenues cut ~$7B including $4.2B reversal.
- Records $5.5B non-cash Q3 charge for COVID inventory write-offs ($4.6B Paxlovid, $0.9B Comirnaty).
- Amended U.S. Paxlovid deal: return ~7.9M EUA courses at year-end; commercial transition Jan 1, 2024.
- Launches cost realignment program targeting $3.5B savings ($1B in 2023, $2.5B in 2024); ~$3B one-time costs.
- Adjusted diluted EPS guidance cut to $1.45-$1.65 from $3.25-$3.45; non-COVID product growth reaffirmed at 6-8%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/78003/000007800323000099/0000078003-23-000099-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/78003/000007800323000099/pfe-20231013.htm
  HTML page:      https://secwatch.observer/filing/0000078003-23-000099

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer